Sofinnova Investments, Inc. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001631134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2025 · 59 positions · Total reported value $1.70B · Top-10 concentration 51.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 67.1% · 13 new · 16 cut · 26 exited

Active Share (vs S&P 500): 99.1% · vs QQQ: 98.7% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +12.4% · vs SPY -2.4% · Prev Value $2.38B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2025 13F filing, Sofinnova Investments, Inc. disclosed 59 equity positions with a combined reported value of $1.70B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 51.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were NTRA ($249.55M), GILD ($139.01M), VERA ($81.19M). By sector, the heaviest allocations are Health Care 86.9%, Other 13.1%. Versus the prior quarter, allocation shifted toward Health Care (+3.5pp) and away from Other (-3.5pp).

Versus the prior quarter, Sofinnova Investments, Inc. opened 13 new positions, trimmed 16 and fully exited 26, a turnover rate of 67.1% of positions. The portfolio's overlap with the prior quarter was 72% of names.

The largest new positions opened in Q3 2025 were VRTX ($46.16M), XBI ($40.08M), GKOS ($25.52M).

Of the 26 positions fully exited versus the prior quarter, the largest were LLY ($75.63M), IWM ($53.95M), INZY ($17.12M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • VRTX VERTEX PHARMACEUTICALS INC · $46.16M
  • XBI SPDR SERIES TRUST · $40.08M
  • GKOS GLAUKOS CORP · $25.52M
  • CELC CELCUITY INC · $12.52M
  • GEHC GE HEALTHCARE TECHNOLOGIES I · $11.35M
  • CMPX COMPASS THERAPEUTICS INC · $7.10M
  • NKTR NEKTAR THERAPEUTICS COM NEW · $6.74M
  • LQDA LIQUIDIA CORPORATION · $5.68M

Fully Exited (vs previous quarter)

  • LLY ELI LILLY & CO · prev qtr: $75.63M
  • IWM ISHARES TR · prev qtr: $53.95M
  • INZY INOZYME PHARMA INC · prev qtr: $17.12M
  • SNDX SYNDAX PHARMACEUTICALS INC · prev qtr: $14.28M
  • REPL REPLIMUNE GROUP INC · prev qtr: $13.94M
  • YMAB Y-MABS THERAPEUTICS INC · prev qtr: $9.90M
  • MTSR METSERA INC · prev qtr: $1.03M
  • GPCR STRUCTURE THERAPEUTICS INC · prev qtr: $712.48K

Insider Transactions (Form 4)

Latest Sofinnova Investments, Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Sofinnova Investments, Inc., based in Menlo Park, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 56 positions worth $1.88B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: MENLO PARK, CA, United States
  • SEC registration: 801-110134 (status: Approved), registered 2017-03-22
  • Regulatory AUM (Form ADV): $5.37B as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 7 private funds, of which 3 hedge funds
  • Website: sofinnova.com

Portfolio Structure

  • 56 positions · $1.88B reported value (Q2 2026)
  • Top 10 holdings = 59.2% of reported value
  • Largest position: NTRA (NATERA INC) at 22.4%
  • Average position size: $33.52M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 13 new, 14 added, 16 reduced, 26 exited
  • 13 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 86.9%
Other 13.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.55M $249.55M 14.66%
14.66%
Hold
2 1.25M $139.01M 8.17%
8.17%
Add
3 2.79M $81.19M 4.77%
4.77%
Hold
4 588.83K $77.61M 4.56%
4.56%
Reduce
5 823.93K $63.21M 3.71%
3.71%
Add
6 1.95M $57.84M 3.40%
3.40%
Reduce
7 569.43K $55.59M 3.27%
3.27%
Add
8 779.62K $52.46M 3.08%
3.08%
Add
9 110.90K $49.60M 2.91%
2.91%
Add
10 393.50K $47.79M 2.81%
2.81%
Add
11 3.15M $47.65M 2.80%
2.80%
Add
12 325.00K $46.92M 2.76%
2.76%
Reduce
13 117.88K $46.16M 2.71%
2.71%
New
14 831.85K $43.21M 2.54%
2.54%
Reduce
15 97.10K $40.71M 2.39%
2.39%
Reduce
16 400.00K $40.08M 2.35%
2.35%
New
17 875.92K $38.16M 2.24%
2.24%
Add
18 150.97K $34.95M 2.05%
2.05%
Reduce
19 1.70M $31.31M 1.84%
1.84%
Hold
20 2.13M $30.56M 1.79%
1.79%
Add
21 312.99K $25.52M 1.50%
1.50%
New
22 922.70K $25.11M 1.48%
1.48%
Reduce
23 246.97K $24.94M 1.47%
1.47%
Add
24 473.62K $22.49M 1.32%
1.32%
Reduce
25 565.42K $22.46M 1.32%
1.32%
Add
26 365.00K $19.97M 1.17%
1.17%
Add
27 2.23M $18.98M 1.11%
1.11%
Reduce
28 900.00K $18.59M 1.09%
1.09%
Add
29 739.88K $18.46M 1.08%
1.08%
Add
30 377.07K $18.02M 1.06%
1.06%
Reduce
31 1.22M $16.62M 0.98%
0.98%
Add
32 166.73K $15.70M 0.92%
0.92%
Reduce
33 104.34K $15.03M 0.88%
0.88%
Reduce
34 440.09K $14.82M 0.87%
0.87%
Reduce
35 2.29M $13.49M 0.79%
0.79%
Hold
36 253.38K $12.52M 0.73%
0.73%
New
37 985.83K $12.47M 0.73%
0.73%
Add
38 186.93K $11.47M 0.67%
0.67%
Reduce
39 151.09K $11.35M 0.67%
0.67%
New
40 166.28K $11.24M 0.66%
0.66%
Reduce
41 172.83K $9.16M 0.54%
0.54%
Add
42 2.43M $8.67M 0.51%
0.51%
Reduce
43 520.24K $8.44M 0.50%
0.50%
Reduce
44 136.86K $7.99M 0.47%
0.47%
Reduce
45 254.27K $7.79M 0.46%
0.46%
Reduce
46 2.03M $7.10M 0.42%
0.42%
New
47 118.42K $6.74M 0.40%
0.40%
New
48 250.00K $5.68M 0.33%
0.33%
New
49 54.20K $5.19M 0.30%
0.30%
Reduce
50 436.05K $5.11M 0.30%
0.30%
Reduce

FAQ

What did Sofinnova Investments, Inc. buy in 2025-Q3?

In its 2025-Q3 13F filing, Sofinnova Investments, Inc. reported 59 equity positions worth $1.70B in aggregate; its largest disclosed positions were NTRA ($249.55M), GILD ($139.01M), VERA ($81.19M).

How large is Sofinnova Investments, Inc.'s portfolio?

Sofinnova Investments, Inc. reported $1.70B of long equity holdings across 59 positions as of 2025-Q3. Top-10 holdings account for 51.3% of reported value.

What is Sofinnova Investments, Inc.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/sofinnova-investments/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →